

This press release is an English translation of a Japanese-language press release. The official language of this press release is Japanese, and the Japanese version takes precedence over the English version in terms of content and interpretation.

<Press Release> September 15th, 2023

> <u>Chordia was nominated as a finalist of</u> the Informa Pharma Intelligence Awards Japan 2023

Kanagawa, Japan, September 15th, 2023 – Chordia Therapeutics Inc. ("Chordia"), announced that our company has been selected as a finalist for Biotech Company of the Year-Sponsored by EPS and Financing Deal of the Year in the Informa Pharma Intelligence Awards 2023.

About the Citeline Pharma Intelligence Awards Japan 2023

The awards are the Japanese version of the Scrip Awards, which have been running for 18 years in the UK and are known worldwide. They recognize excellence and innovation by Japanese pharmaceutical and biotech companies and highlight Japan's important role in the global healthcare industry. The purpose of the awards is to reflect together on the achievements of the previous year and to honor the companies and individuals' industry-wide who are paving the way for the future of the pharmaceutical industry.

Website:https://www.citeline.com/ja-jp/awards/citelinepharmaintelligenceawards

About Chordia Therapeutics

Chordia was established in November 2017 at Shonan Health Innovation Park ("Shonan iPark") in Fujisawa, Kanagawa Prefecture, as a biotech company engaged in the research and development of novel therapies for cancers, with the goal of researching and developing first-in-class anti-cancer drugs and creating innovative new drugs.

In addition to its leading program for CTX-712, Chordia is engaged in the research of several developments in our pipeline, including CTX-439, a CDK12 inhibitor, which is expected to be effective in cancers with specific abnormalities, as well as GCN2 inhibitors.

vember 2017
-1, Muraoka-Higashi 2-chome, Fujisawa,
nagawa 251-0012, Japan
roshi Miyake, Representative Director
ps://www.chordiatherapeutics.com/en/

For more information, contact, IR Mizobe: ir@chordiatherapeutics.com